Herceptin + 17-AAG Combination BT-474 Tumors

Slides:

Advertisements

Similar presentations

Supplemental figure 1 ROS production in MM cell line (KMM1) treated with bortezomib and DCA. ROS production was marginally increased by DCA in combination.

Advertisements

Supplemental Figure 1 A No. at risk T T T

P-4E-BP1/4E-BP1P-p70 S6K/p70 S6K ND cleaved PARP/PARPLC3II/LC3I Supplementary Figure 1 Relative levels A BC P-Akt/Akt.

NPV-BEZ235PKI-587 GDC-0980PD Supplemental Figure S1 Structures of Inhibitors NVP-BEZ235; PKI-587; GDC-0980 and PD

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

Figure 1. Figure : 2 BT4 before bt b NR15 preT NR15 M6 BT7 preT BT7 before bt BT7 after bt BT7 postT NR19 preT NR19 M4 NR19.

Supplementary Figures&Legends. Figure1. Subcutaneous xenograft tumor models of the control group.

Adipose PancreasAorta MuscleHeart Liver LungKidney Testis Spleen Brian 18S p55 γ p55 α Figure S1 Tissue distribution of p55 . (A) Representative RT-PCR.

Supplemental Table 1 Source and authentication of cell lines.

Con WTTM Supplementary Figure 1 Supplementary Figure 1. Tumor histopathology of the lungs. (a) Histological examination of lungs of 52-week-old K- ras.

Figure 1 B D DOX ( μ M) C Cell Proliferation (% Con) MCF-7MCF-7/DOX DOX ( μ M) 0.03% 38.79% 0.15% 0.10% 0.20% 0.05%

A B A Stat3:Stat3 Supershift  -ST3 Free probe BP1-102 (µM) Stat3:Stat3 % of Cont Supplementary Figures Fig. S1 -

Figure1 HER2 SKBr3 PC3 A. SKBr3 cells Figure (µM) Penetratin control % of control (µM)

ПЕЧЕНЬ 9. Закладка печени в период эмбрионального развития.

The reading is 7.38 mm. The reading is 7.72 mm.

Shimura Supplemental Figure 1

Volume 20, Issue 4, Pages (October 2011)

Supplementary Figure 1. A B C MP-MRT-AN KP-MRT-NS KP-MRT-RY KP-MRT-YM

A B C Volume (%) Size (nm) Time (h) 3 x x x 1010

Relative FOXM1and Met protein levels (normalized to GAPDH)

Supplementary Figure 1 Lapatinib nM mM pEGFR MDA-MB231 EGFR pEGFR

Invest. Ophthalmol. Vis. Sci ;52(6): doi: /iovs Figure Legend:

A. B. C. D E. F. 100 GSK3β pGSK3β pAkt Akt p38/ SAPK

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

Covariate AD N (%) SCC N (%) p-values Sex 63/63 96/ M

Yunguang Sun, PhD, Luigi Moretti, MD, Nicholas J

3-D Shapes and Volumes General Formula for Volume: Volume for “pointy” objects:

MET Tyrosine Kinase Inhibitor Crizotinib (PF ) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations

Ming Hong Shen, Paulina Samsel, Louise L

Figure S3. in vivo Study of ABT-263 or SAR in the RS4;11 model in mice

Volume 191, Issue 1, Pages (January 2014)

Volume 20, Issue 2, Pages (August 2011)

Days after cell inoculation Days after cell inoculation

Days after cell inoculation Days after cell inoculation

Volume 128, Issue 5, Pages (May 2005)

The C-terminus of Hsp70-Interacting Protein Promotes Met Receptor Degradation Kang Won Jang, PhD, Jeong Eun Lee, MD, Sun Young Kim, MD, Min-Woong Kang,

Volume 19, Issue 1, Pages (January 2011)

Figure 2S (Supplementary Data)

Supplementary Figure 2. AKT1 AKT1 AKT2 pAKT ERK pERK A1847 A2780 CaOV3

The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.

TBP 200 LC2/ad MGH134 MGH134 CCDC6-RET MGH134 EV CCDC6-RET PC9

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Volume 15, Issue 5, Pages (May 2009)

Volume 20, Issue 4, Pages (October 2011)

Anti-tumor effect of anti-PD-1 antibody against SCC3 tumor

Supp. Figure 1 MM-302 trastuzumab Vessels Hoechst Merge.

Supplemental Figure 6 Supplemental Figure 6. Treatment with erlotinib plus TAS-115 inhibits the growth of PC-9/HGF tumors in vivo. (A, B) Nude mice bearing.

A 4h of treatment 72h of treatment 1mM PI3Kbi

Vehicle Akti 0’ 2’ 5’ 10’ 0’ 2’ 5’ 10’ AktT308 β-actin GSK3βS9 β-actin

Effect of MI-773 dosing on long-term efficacy.

C A B * * * * HCC1954 HCC1569 Supplementary-Figure S5 Tumor cells sc.

Induction of apoptosis by nelfinavir and bortezomib

Metformin and rapamycin decreased tumor weights in obese prediabetic mice. Metformin and rapamycin decreased tumor weights in obese prediabetic mice. A:

Supplement Figure.1.

pERK ERK pSTAT1 STAT1 pSTAT3 STAT3 pAKT AKT

Comparison of a Treatment Strategy Combining CCI-779 Plus DTIC Versus DTIC Monotreatment in Human Melanoma in SCID Mice Christiane Thallinger, Johannes.

The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.

Active AR signaling in enzalutamide-resistant xenograft tumors.

Antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against xenograft models sensitive.

Volume 7, Issue 6, Pages (June 2014)

Pharmacological targeting of CDs promotes response to KRASG12C inhibition in vivo. Pharmacological targeting of CDs promotes response to KRASG12C inhibition.

MEDI4736 shows antitumor activity in xenograft mouse models of human cancer. MEDI4736 shows antitumor activity in xenograft mouse models of human cancer.

The combination of trastuzumab and SU11274 abrogate Akt phosphorylation. The combination of trastuzumab and SU11274 abrogate Akt phosphorylation. Serum-starved.

Mean body weights (grams) of athymic female mice implanted with MDA-MB-231 breast carcinoma xenografts. Mean body weights (grams) of athymic female mice.

SW620 xenografts treated with combination siKRAS+siPIK3CA/B.

RhuαVEGF and rhuαVEGF/paclitaxel mediated growth inhibition in an androgen-independent prostate cancer xenograft model. rhuαVEGF and rhuαVEGF/paclitaxel.

e a b c d unstimulated +fMLP T308P-Akt S473P-Akt Akt (min)

PDL192 and inhibit the growth of xenograft tumors.

In vivo effect of KIN-193 on PTEN-deficient tumors.

Fig. 5 DDO-5936 dose-dependently impairs the growth of xenografted HCT116 cells in nude mice. DDO-5936 dose-dependently impairs the growth of xenografted.

Presentation transcript:

Herceptin + 17-AAG Combination BT-474 Tumors Supplemental Figure 1 A. 100 200 300 400 500 600 10 20 30 40 50 Day Tumor volume (mm3) Control 17-AAG 100mg/kg 2x/wk Herceptin 20mg/kg 2x/wk Combination B. BT-474 Tumors Herceptin + 17-AAG Combination BT-474 Tumors P-AKT after Herceptin 20mg/kg x1 -0- ---3--- ---6--- ---12--- ---24--- Time(hr) P-AKT (473) p85-PI3K

MEF-p95-HER2 Xenograft Tumors Supplemental Figure 2 MEF-p95-HER2 Xenograft Tumors ----0---- ----6---- ----24---- Time(hr) P95-HER2 P-p95-HER2

Supplemental Figure 3 MEF-p95-HER2 500nM SNX-2112 MCF-7-p95-HER2 500nM SNX-2112 0 6 12 24 48 Time(hr) 0 6 12 24 48 p95 P-p95 P-AKT AKT P-ERK ERK